ABVC BioPharma Statistics
Total Valuation
ABVC BioPharma has a market cap or net worth of $56.80 million. The enterprise value is $57.13 million.
Important Dates
The last earnings date was Monday, November 3, 2025, before market open.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABVC BioPharma has 23.57 million shares outstanding. The number of shares has increased by 71.54% in one year.
| Current Share Class | 23.57M |
| Shares Outstanding | 23.57M |
| Shares Change (YoY) | +71.54% |
| Shares Change (QoQ) | +33.76% |
| Owned by Insiders (%) | 11.46% |
| Owned by Institutions (%) | 3.33% |
| Float | 20.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 54.62 |
| Forward PS | n/a |
| PB Ratio | 4.92 |
| P/TBV Ratio | 4.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 71.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.17.
| Current Ratio | 0.63 |
| Quick Ratio | 0.04 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.18 |
Financial Efficiency
Return on equity (ROE) is -47.71% and return on invested capital (ROIC) is -22.17%.
| Return on Equity (ROE) | -47.71% |
| Return on Assets (ROA) | -17.22% |
| Return on Invested Capital (ROIC) | -22.17% |
| Return on Capital Employed (ROCE) | -33.47% |
| Revenue Per Employee | $41,996 |
| Profits Per Employee | -$267,220 |
| Employee Count | 19 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ABVC BioPharma has paid $24,154 in taxes.
| Income Tax | 24,154 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +340.59% in the last 52 weeks. The beta is 0.24, so ABVC BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +340.59% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 34.73 |
| Average Volume (20 Days) | 56,411 |
Short Selling Information
The latest short interest is 385,898, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 385,898 |
| Short Previous Month | 390,678 |
| Short % of Shares Out | 1.64% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 5.96 |
Income Statement
In the last 12 months, ABVC BioPharma had revenue of $797,916 and -$5.08 million in losses. Loss per share was -$0.29.
| Revenue | 797,916 |
| Gross Profit | 797,916 |
| Operating Income | -4.91M |
| Pretax Income | -5.34M |
| Net Income | -5.08M |
| EBITDA | -4.88M |
| EBIT | -4.91M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $257,243 in cash and $2.47 million in debt, giving a net cash position of -$2.21 million or -$0.09 per share.
| Cash & Cash Equivalents | 257,243 |
| Total Debt | 2.47M |
| Net Cash | -2.21M |
| Net Cash Per Share | -$0.09 |
| Equity (Book Value) | 14.49M |
| Book Value Per Share | 0.51 |
| Working Capital | -2.43M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.27M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -615.35% |
| Pretax Margin | -668.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABVC BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -71.54% |
| Shareholder Yield | -71.54% |
| Earnings Yield | -9.24% |
| FCF Yield | -4.13% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
ABVC BioPharma has an Altman Z-Score of -3.54 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.54 |
| Piotroski F-Score | 4 |